Search

Your search keyword '"Caskey, F."' showing total 161 results
Start Over Author "Caskey, F."
161 results on '"Caskey, F."'

2. The relationship between uremic toxins and symptoms in older men and women with advanced chronic kidney disease

Author

Massy Z. A., Chesnaye N. C., Larabi I. A., Dekker F. W., Evans M., Caskey F. J., Torino C., Porto G., Szymczak M., Drechsler C., Wanner C., Jager K. J., Alvarez J. C., Schneider A., Torp A., Iwig B., Perras B., Marx C., Blaser C., Emde C., Krieter D., Fuchs D., Irmler E., Platen E., Schmidt-Gurtler H., Schlee H., Naujoks H., Schlee I., Casar S., Beige J., Rothele J., Mazur J., Hahn K., Blouin K., Neumeier K., Anding-Rost K., Schramm L., Hopf M., Wuttke N., Frischmuth N., Ichtiaris P., Kirste P., Schulz P., Aign S., Biribauer S., Manan S., Roser S., Heidenreich S., Palm S., Schwedler S., Delrieux S., Renker S., Schattel S., Stephan T., Schmiedeke T., Weinreich T., Leimbach T., Stovesand T., Bahner U., Seeger W., Cupisti A., Sagliocca A., Ferraro A., Mele A., Naticchia A., Cosaro A., Ranghino A., Stucchi A., Pignataro A., De Blasio A., Pani A., Tsalouichos A., Bellasi A., Raffaele Di Iorio B., Butti A., Abaterusso C., Somma C., D'Alessandro C., Zullo C., Pozzi C., Bergamo D., Ciurlino D., Motta D., Russo D., Favaro E., Vigotti F., Ansali F., Conte F., Cianciotta F., Giacchino F., Cappellaio F., Pizzarelli F., Greco G., Bigatti G., Marinangeli G., Cabiddu G., Fumagalli G., Caloro G., Piccoli G., Capasso G., Gambaro G., Tognarelli G., Bonforte G., Conte G., Toscano G., Del Rosso G., Capizzi I., Baragetti I., Oldrizzi L., Gesualdo L., Biancone L., Magnano M., Ricardi M., Di Bari M., Laudato M., Luisa Sirico M., Ferraresi M., Provenzano M., Malaguti M., Palmieri N., Murrone P., Cirillo P., Dattolo P., Acampora P., Nigro R., Boero R., Scarpioni R., Sicoli R., Malandra R., Savoldi S., Bertoli S., Borrelli S., Maxia S., Maffei S., Mangano S., Cicchetti T., Rappa T., Palazzo V., De Simone W., Schrander A., Van Dam B., Siegert C., Gaillard C., Beerenhout C., Verburgh C., Janmaat C., Hoogeveen E., Hoorn E., Boots J., Boom H., Eijgenraam J. -W., Kooman J., Rotmans J., Vogt L., Raasveld M., Vervloet M., Van Buren M., Van Diepen M., Leurs P., Voskamp P., Blankestijn P., Van Esch S., Boorsma S., Berger S., Konings C., Aydin Z., Musiala A., Szymczak A., Olczyk E., Augustyniak-Bartosik H., Miskowiec-Wisniewska I., Manitius J., Pondel J., Jedrzejak K., Nowanska K., Nowak L., Durlik M., Dorota S., Nieszporek T., Heleniak Z., Jonsson A., Blom A. -L., Rogland B., Wallquist C., Vargas D., Dimeny E., Sundelin F., Uhlin F., Welander G., Bascaran Hernandez I., Grontoft K. -C., Stendahl M., Svensson M., Heimburger O., Kashioulis P., Melander S., Almquist T., Jensen U., Woodman A., McKeever A., Ullah A., McLaren B., Harron C., Barrett C., O'Toole C., Summersgill C., Geddes C., Glowski D., McGlynn D., Sands D., Roy G., Hirst G., King H., McNally H., Masri-Senghor H., Murtagh H., Rayner H., Turner J., Wilcox J., Berdeprado J., Wong J., Banda J., Jones K., Haydock L., Wilkinson L., Carmody M., Weetman M., Joinson M., Dutton M., Matthews M., Morgan N., Bleakley N., Cockwell P., Roderick P., Mason P., Kalra P., Sajith R., Chapman S., Navjee S., Crosbie S., Brown S., Tickle S., Mathavakkannan S., Kuan Y., Massy, Z. A., Chesnaye, N. C., Larabi, I. A., Dekker, F. W., Evans, M., Caskey, F. J., Torino, C., Porto, G., Szymczak, M., Drechsler, C., Wanner, C., Jager, K. J., Alvarez, J. C., Schneider, A., Torp, A., Iwig, B., Perras, B., Marx, C., Blaser, C., Emde, C., Krieter, D., Fuchs, D., Irmler, E., Platen, E., Schmidt-Gurtler, H., Schlee, H., Naujoks, H., Schlee, I., Casar, S., Beige, J., Rothele, J., Mazur, J., Hahn, K., Blouin, K., Neumeier, K., Anding-Rost, K., Schramm, L., Hopf, M., Wuttke, N., Frischmuth, N., Ichtiaris, P., Kirste, P., Schulz, P., Aign, S., Biribauer, S., Manan, S., Roser, S., Heidenreich, S., Palm, S., Schwedler, S., Delrieux, S., Renker, S., Schattel, S., Stephan, T., Schmiedeke, T., Weinreich, T., Leimbach, T., Stovesand, T., Bahner, U., Seeger, W., Cupisti, A., Sagliocca, A., Ferraro, A., Mele, A., Naticchia, A., Cosaro, A., Ranghino, A., Stucchi, A., Pignataro, A., De Blasio, A., Pani, A., Tsalouichos, A., Bellasi, A., Raffaele Di Iorio, B., Butti, A., Abaterusso, C., Somma, C., D'Alessandro, C., Zullo, C., Pozzi, C., Bergamo, D., Ciurlino, D., Motta, D., Russo, D., Favaro, E., Vigotti, F., Ansali, F., Conte, F., Cianciotta, F., Giacchino, F., Cappellaio, F., Pizzarelli, F., Greco, G., Bigatti, G., Marinangeli, G., Cabiddu, G., Fumagalli, G., Caloro, G., Piccoli, G., Capasso, G., Gambaro, G., Tognarelli, G., Bonforte, G., Conte, G., Toscano, G., Del Rosso, G., Capizzi, I., Baragetti, I., Oldrizzi, L., Gesualdo, L., Biancone, L., Magnano, M., Ricardi, M., Di Bari, M., Laudato, M., Luisa Sirico, M., Ferraresi, M., Provenzano, M., Malaguti, M., Palmieri, N., Murrone, P., Cirillo, P., Dattolo, P., Acampora, P., Nigro, R., Boero, R., Scarpioni, R., Sicoli, R., Malandra, R., Savoldi, S., Bertoli, S., Borrelli, S., Maxia, S., Maffei, S., Mangano, S., Cicchetti, T., Rappa, T., Palazzo, V., De Simone, W., Schrander, A., Van Dam, B., Siegert, C., Gaillard, C., Beerenhout, C., Verburgh, C., Janmaat, C., Hoogeveen, E., Hoorn, E., Boots, J., Boom, H., Eijgenraam, J. -W., Kooman, J., Rotmans, J., Vogt, L., Raasveld, M., Vervloet, M., Van Buren, M., Van Diepen, M., Leurs, P., Voskamp, P., Blankestijn, P., Van Esch, S., Boorsma, S., Berger, S., Konings, C., Aydin, Z., Musiala, A., Szymczak, A., Olczyk, E., Augustyniak-Bartosik, H., Miskowiec-Wisniewska, I., Manitius, J., Pondel, J., Jedrzejak, K., Nowanska, K., Nowak, L., Durlik, M., Dorota, S., Nieszporek, T., Heleniak, Z., Jonsson, A., Blom, A. -L., Rogland, B., Wallquist, C., Vargas, D., Dimeny, E., Sundelin, F., Uhlin, F., Welander, G., Bascaran Hernandez, I., Grontoft, K. -C., Stendahl, M., Svensson, M., Heimburger, O., Kashioulis, P., Melander, S., Almquist, T., Jensen, U., Woodman, A., Mckeever, A., Ullah, A., Mclaren, B., Harron, C., Barrett, C., O'Toole, C., Summersgill, C., Geddes, C., Glowski, D., Mcglynn, D., Sands, D., Roy, G., Hirst, G., King, H., Mcnally, H., Masri-Senghor, H., Murtagh, H., Rayner, H., Turner, J., Wilcox, J., Berdeprado, J., Wong, J., Banda, J., Jones, K., Haydock, L., Wilkinson, L., Carmody, M., Weetman, M., Joinson, M., Dutton, M., Matthews, M., Morgan, N., Bleakley, N., Cockwell, P., Roderick, P., Mason, P., Kalra, P., Sajith, R., Chapman, S., Navjee, S., Crosbie, S., Brown, S., Tickle, S., Mathavakkannan, S., Kuan, Y., Nephrology, ACS - Diabetes & metabolism, Medical Informatics, APH - Methodology, APH - Aging & Later Life, APH - Quality of Care, APH - Global Health, APH - Health Behaviors & Chronic Diseases, and ACS - Pulmonary hypertension & thrombosis

Subjects
Transplantation, Nephrology, uremic toxins, CKD, symptoms, symptom, elderly
Abstract

Background Patients with stage 4/5 chronic kidney disease (CKD) suffer from various symptoms. The retention of uremic solutes is thought to be associated with those symptoms. However, there are relatively few rigorous studies on the potential links between uremic toxins and symptoms in patients with CKD. Methods The EQUAL study is an ongoing observational cohort study of non-dialyzed patients with stage 4/5 CKD. EQUAL patients from Germany, Poland, Sweden and the UK were included in the present study (n = 795). Data and symptom self-report questionnaires were collected between April 2012 and September 2020. Baseline uric acid and parathyroid hormone and 10 uremic toxins were quantified. We tested the association between uremic toxins and symptoms and adjusted P-values for multiple testing. Results Symptoms were more frequent in women than in men with stage 4/5 CKD, while levels of various uremic toxins were higher in men. Only trimethylamine N-oxide (TMAO; positive association with fatigue), p-cresyl sulfate (PCS) with constipation and 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid (negative association with shortness of breath) demonstrated moderately strong associations with symptoms in adjusted analyses. The association of phenylacetylglutamine with shortness of breath was consistent in both sexes, although it only reached statistical significance in the full population. In contrast, TMAO (fatigue) and PCS and phenylacetylglutamine (constipation) were only associated with symptoms in men, who presented higher serum levels than women. Conclusion Only a limited number of toxins were associated with symptoms in persons with stage 4/5 CKD. Other uremic toxins, uremia-related factors or psychosocial factors not yet explored might contribute to symptom burden.

Published
2022

4. Converting from face-to-face to postal follow-up and its effects on participant retention, response rates and errors:lessons from the EQUAL study in the UK

Author

Gates, E., Hole, B., Hayward, S., Chesnaye, N.C., Meuleman, Y., Dekker, F.W., Evans, M., Heimburger, O., Torino, C., Porto, G., Szymczak, M., Drechsler, C., Wanner, C., Jager, K.J., Roderick, P., Caskey, F., EQUAL Investigators, Medical Informatics, ACS - Pulmonary hypertension & thrombosis, APH - Aging & Later Life, APH - Methodology, APH - Quality of Care, APH - Global Health, and APH - Health Behaviors & Chronic Diseases

Subjects
Medicine (General), retention, Epidemiology, Errors, Health Informatics, Face-to-face, R5-920, response rates, Chronic kidney disease, follow-up, Humans, errors, Prospective Studies, Pandemics, prospective cohort study, SARS-CoV-2, Follow-up, COVID-19, Response rates, United Kingdom, Prospective cohort study, Retention, Optometry, Psychology, chronic kidney disease, Follow-Up Studies
Abstract

Background Prospective cohort studies are challenging to deliver, with one of the main difficulties lying in retention of participants. The need to socially distance during the COVID-19 pandemic has added to this challenge. The pre-COVID-19 adaptation of the European Quality (EQUAL) study in the UK to a remote form of follow-up for efficiency provides lessons for those who are considering changing their study design. Methods The EQUAL study is an international prospective cohort study of patients ≥65 years of age with advanced chronic kidney disease. Initially, patients were invited to complete a questionnaire (SF-36, Dialysis Symptom Index and Renal Treatment Satisfaction Questionnaire) at research clinics every 3–6 months, known as “traditional follow-up” (TFU). In 2018, all living patients were invited to switch to “efficient follow-up” (EFU), which used an abbreviated questionnaire consisting of SF-12 and Dialysis Symptom Index. These were administered centrally by post. Response rates were calculated using returned questionnaires as a proportion of surviving invitees, and error rates presented as the average percentage of unanswered questions or unclear answers, of total questions in returned questionnaires. Response and error rates were calculated 6-monthly in TFU to allow comparisons with EFU. Results Of the 504 patients initially recruited, 236 were still alive at the time of conversion to EFU; 111 of these (47%) consented to the change in follow-up. In those who consented, median TFU was 34 months, ranging from 0 to 42 months. Their response rates fell steadily from 88% (98/111) at month 0 of TFU, to 20% (3/15) at month 42. The response rate for the first EFU questionnaire was 60% (59/99) of those alive from TFU. With this improvement in response rates, the first EFU also lowered errors to baseline levels seen in early follow-up, after having almost trebled throughout traditional follow-up. Conclusions Overall, this study demonstrates that administration of shorter follow-up questionnaires by post rather than in person does not negatively impact patient response or error rates. These results may be reassuring for researchers who are trying to limit face-to-face contact with patients during the COVID-19 pandemic.

Published
2022

6. POS-968 COVID-19 PANDEMIC IDENTIFIES SIGNIFICANT GLOBAL INEQUITIES IN HEMODIALYSIS CARE IN LOW AND LOWER MIDDLE INCOME COUNTRIES - AN ISN/DOPPS SURVEY

Author

Tannor, E.K., primary, BIEBER, B., additional, Luyckx, V., additional, Shah, D.S., additional, Liew, A., additional, Evans, R., additional, Aylward, R., additional, Guedes, M., additional, Pisoni, R.L., additional, Robinson, B.M., additional, Caskey, F., additional, Jha, V., additional, Pecoits-Filho, R., additional, and Dreyer, G., additional

Published
2022
Full Text
View/download PDF

7. POS-926 IN-CENTRE HAEMODIALYSIS CENTRES VARIABLY AFFECTED BY THE CORONAVIRUS-2019 PANDEMIC IN DIFFERENT REGIONS OF THE WORLD: THE INTERNATIONAL SOCIETY OF NEPHROLOGY-DIALYSIS OUTCOMES PRACTICE PATTERNS STUDY SURVEY

Author

AYLWARD, R., primary, BIEBER, B., additional, Guedes, M., additional, Pisoni, R., additional, Koranteng Tannor, E., additional, Dreyer, G., additional, Liew, A., additional, Luyckx, V., additional, Singh, D., additional, Phiri, C., additional, Evans, R., additional, Jha, V., additional, Pecoits-Filho, R., additional, Robinson, B., additional, and Caskey, F., additional

Published
2022
Full Text
View/download PDF

8. Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey.

Author

Yeung E., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G., Bellorin-Font E., Benghanem Gharbi M., Davison S., Ghnaimat M., Harden P., Jha V., Kalantar-Zadeh K., Kerr P., Klarenbach S., Kovesdy C., Luyckx V., Neuen B., O'Donoghue D., Ossareh S., Perl J., Ur Rashid H., Rondeau E., See E., Saad S., Sola L., Tchokhonelidze I., Tesar V., Tungsanga K., Turan Kazancioglu R., Wang A.Y.-M., Wiebe N., Yang C.-W., Zemchenkov A., Zhao M., Jager K.J., Caskey F., Perkovic V., Jindal K., Okpechi I.G., Tonelli M., Feehally J., Harris D.C.H., Johnson D., Yeung E., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G., Bellorin-Font E., Benghanem Gharbi M., Davison S., Ghnaimat M., Harden P., Jha V., Kalantar-Zadeh K., Kerr P., Klarenbach S., Kovesdy C., Luyckx V., Neuen B., O'Donoghue D., Ossareh S., Perl J., Ur Rashid H., Rondeau E., See E., Saad S., Sola L., Tchokhonelidze I., Tesar V., Tungsanga K., Turan Kazancioglu R., Wang A.Y.-M., Wiebe N., Yang C.-W., Zemchenkov A., Zhao M., Jager K.J., Caskey F., Perkovic V., Jindal K., Okpechi I.G., Tonelli M., Feehally J., Harris D.C.H., and Johnson D.

Abstract

The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide. A cross-sectional global survey. Key stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included. Primary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries. 160 countries (covering 98% of the world's population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries. Significant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly for those in low-income and lower-middle-income countries.Copyright © Autho

Published
2021

9. Availability, coverage, and scope of health information systems for kidney care across world countries and regions.

Author

Kazancioglu R.T., Rashid H.U., Rondeau E., Syed S., Sola L., Tchokhonelidze I., Tesar V., Tungsanga K., Wang A.Y.-M., Johnson D.W., Harris D.C., Feehally J., Tonelli M., Okpechi I.G., Jindal K.K., Perkovic V., Caskey F., Jager K.J., Zhao M.-H., Zemchenkov A., Yang C.-W., See E.J., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Davison S., Ghnaimat M., Harden P., Htay H., Jha V., Kalantar-Zadeh K., Kerr P.G., Klarenbach S., Kovesdy C.P., Luyckx V., Neuen B., O'Donoghue D., Ossareh S., Perl J., Kazancioglu R.T., Rashid H.U., Rondeau E., Syed S., Sola L., Tchokhonelidze I., Tesar V., Tungsanga K., Wang A.Y.-M., Johnson D.W., Harris D.C., Feehally J., Tonelli M., Okpechi I.G., Jindal K.K., Perkovic V., Caskey F., Jager K.J., Zhao M.-H., Zemchenkov A., Yang C.-W., See E.J., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Davison S., Ghnaimat M., Harden P., Htay H., Jha V., Kalantar-Zadeh K., Kerr P.G., Klarenbach S., Kovesdy C.P., Luyckx V., Neuen B., O'Donoghue D., Ossareh S., and Perl J.

Abstract

BACKGROUND: Health information systems (HIS) are fundamental tools for the surveillance of health services, estimation of disease burden and prioritization of health resources. Several gaps in the availability of HIS for kidney disease were highlighted by the first iteration of the Global Kidney Health Atlas. METHOD(S): As part of its second iteration, the International Society of Nephrology conducted a cross-sectional global survey between July and October 2018 to explore the coverage and scope of HIS for kidney disease, with a focus on kidney replacement therapy (KRT). RESULT(S): Out of a total of 182 invited countries, 154 countries responded to questions on HIS (85% response rate). KRT registries were available in almost all high-income countries, but few low-income countries, while registries for non-dialysis chronic kidney disease (CKD) or acute kidney injury (AKI) were rare. Registries in high-income countries tended to be national, in contrast to registries in low-income countries, which often operated at local or regional levels. Although cause of end-stage kidney disease, modality of KRT and source of kidney transplant donors were frequently reported, few countries collected data on patient-reported outcome measures and only half of low-income countries recorded process-based measures. Almost no countries had programs to detect AKI and practices to identify CKD-targeted individuals with diabetes, hypertension and cardiovascular disease, rather than members of high-risk ethnic groups. CONCLUSION(S): These findings confirm significant heterogeneity in the global availability of HIS for kidney disease and highlight important gaps in their coverage and scope, especially in low-income countries and across the domains of AKI, non-dialysis CKD, patient-reported outcomes, process-based measures and quality indicators for KRT service delivery.Copyright © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Published
2021

10. Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey

Author

Yeung, E, Bello, AK, Levin, A, Lunney, M, Osman, MA, Ye, F, Ashuntantang, G, Bellorin-Font, E, Benghanem Gharbi, M, Davison, S, Ghnaimat, M, Harden, P, Jha, V, Kalantar-Zadeh, K, Kerr, P, Klarenbach, S, Kovesdy, C, Luyckx, V, Neuen, B, O'Donoghue, D, Ossareh, S, Perl, J, Ur Rashid, H, Rondeau, E, See, E, Saad, S, Sola, L, Tchokhonelidze, I, Tesar, V, Tungsanga, K, Turan Kazancioglu, R, Wang, AY-M, Wiebe, N, Yang, C-W, Zemchenkov, A, Zhao, M, Jager, KJ, Caskey, F, Perkovic, V, Jindal, K, Okpechi, IG, Tonelli, M, Feehally, J, Harris, DCH, Johnson, D, Yeung, E, Bello, AK, Levin, A, Lunney, M, Osman, MA, Ye, F, Ashuntantang, G, Bellorin-Font, E, Benghanem Gharbi, M, Davison, S, Ghnaimat, M, Harden, P, Jha, V, Kalantar-Zadeh, K, Kerr, P, Klarenbach, S, Kovesdy, C, Luyckx, V, Neuen, B, O'Donoghue, D, Ossareh, S, Perl, J, Ur Rashid, H, Rondeau, E, See, E, Saad, S, Sola, L, Tchokhonelidze, I, Tesar, V, Tungsanga, K, Turan Kazancioglu, R, Wang, AY-M, Wiebe, N, Yang, C-W, Zemchenkov, A, Zhao, M, Jager, KJ, Caskey, F, Perkovic, V, Jindal, K, Okpechi, IG, Tonelli, M, Feehally, J, Harris, DCH, and Johnson, D

Abstract

OBJECTIVES: The Global Kidney Health Atlas (GKHA) is a multinational, cross-sectional survey designed to assess the current capacity for kidney care across all world regions. The 2017 GKHA involved 125 countries and identified significant gaps in oversight, funding and infrastructure to support care for patients with kidney disease, especially in lower-middle-income countries. Here, we report results from the survey for the second iteration of the GKHA conducted in 2018, which included specific questions about health financing and oversight of end-stage kidney disease (ESKD) care worldwide. SETTING: A cross-sectional global survey. PARTICIPANTS: Key stakeholders from 182 countries were invited to participate. Of those, stakeholders from 160 countries participated and were included. PRIMARY OUTCOMES: Primary outcomes included cost of kidney replacement therapy (KRT), funding for dialysis and transplantation, funding for conservative kidney management, extent of universal health coverage, out-of-pocket costs for KRT, within-country variability in ESKD care delivery and oversight systems for ESKD care. Outcomes were determined from a combination of desk research and input from key stakeholders in participating countries. RESULTS: 160 countries (covering 98% of the world's population) responded to the survey. Economic factors were identified as the top barrier to optimal ESKD care in 99 countries (64%). Full public funding for KRT was more common than for conservative kidney management (43% vs 28%). Among countries that provided at least some public coverage for KRT, 75% covered all citizens. Within-country variation in ESKD care delivery was reported in 40% of countries. Oversight of ESKD care was present in all high-income countries but was absent in 13% of low-income, 3% of lower-middle-income, and 10% of upper-middle-income countries. CONCLUSION: Significant gaps and variability exist in the public funding and oversight of ESKD care in many countries, particularly f

Published
2021

17. Status of care for end stage kidney disease in countries and regions worldwide: International cross sectional survey.

Author

Rashid H.U., Klarenbach S., Kovesdy C.P., Luyckx V.A., Neuen B.L., O'Donoghue D., Ossareh S., Perl J., Rondeau E., Johnson D.W., Harris D.C., Feehally J., Tonelli M., Okpechi I.G., Jindal K.K., Perkovic V., Caskey F., Jager K.J., Zhao M.-H., Zemchenkov A., Yang C.-W., Wiebe N., Wang A.Y.-M., Turan Kazancioglu R., Tungsanga K., Tesar V., Tchokhonelidze I., Sola L., Saad S., See E., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Davison S.N., Ghnaimat M., Harden P., Htay H., Jha V., Kalantar-Zadeh K., Kerr P.G., Rashid H.U., Klarenbach S., Kovesdy C.P., Luyckx V.A., Neuen B.L., O'Donoghue D., Ossareh S., Perl J., Rondeau E., Johnson D.W., Harris D.C., Feehally J., Tonelli M., Okpechi I.G., Jindal K.K., Perkovic V., Caskey F., Jager K.J., Zhao M.-H., Zemchenkov A., Yang C.-W., Wiebe N., Wang A.Y.-M., Turan Kazancioglu R., Tungsanga K., Tesar V., Tchokhonelidze I., Sola L., Saad S., See E., Bello A.K., Levin A., Lunney M., Osman M.A., Ye F., Ashuntantang G.E., Bellorin-Font E., Benghanem Gharbi M., Davison S.N., Ghnaimat M., Harden P., Htay H., Jha V., Kalantar-Zadeh K., and Kerr P.G.

Abstract

Objective To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis and transplantation) and conservative kidney management. Design International cross sectional survey. Setting International Society of Nephrology (ISN) survey of 182 countries from July to September 2018. Participants Key stakeholders identified by ISN's national and regional leaders. Main outcome measures Markers of national capacity to deliver core components of kidney replacement therapy and conservative kidney management. Results Responses were received from 160 (87.9%) of 182 countries, comprising 97.8% (7338.5 million of 7501.3 million) of the world's population. A wide variation was found in capacity and structures for kidney replacement therapy and conservative kidney management-namely, funding mechanisms, health workforce, service delivery, and available technologies. Information on the prevalence of treated end stage kidney disease was available in 91 (42%) of 218 countries worldwide. Estimates varied more than 800-fold from 4 to 3392 per million population. Rwanda was the only low income country to report data on the prevalence of treated disease; 5 (<10%) of 53 African countries reported these data. Of 159 countries, 102 (64%) provided public funding for kidney replacement therapy. Sixty eight (43%) of 159 countries charged no fees at the point of care delivery and 34 (21%) made some charge. Haemodialysis was reported as available in 156 (100%) of 156 countries, peritoneal dialysis in 119 (76%) of 156 countries, and kidney transplantation in 114 (74%) of 155 countries. Dialysis and kidney transplantation were available to more than 50% of patients in only 108 (70%) and 45 (29%) of 154 countries that offered these services, respectively. Conservative kidney management was available in 124 (81%) of 154 countries. Worldwide, the median number of nephrologists was 9.96 per million population, which varied with i

Published
2019

21. The effect of oral bisphosphonates on acute kidney injury, gastrointestinal events and hypocalcaemia in patients with chronic kidney disease

Author

Robinson, D, Ali, M, Pallares, N, Tebe, C, Cooper, C, Abrahamsen, B, Caskey, F, Ben-Shlomo, Y, Judge, A, Javaid, M, Diez-Perez, A, and Prieto-Alhambra, D

Abstract

Oral bisphosphonates (oBP) are contraindicated in patients with severe chronic kidney disease (CKD), but there is a lack of data on safety in this area. We aimed to study the association between oBP use and risk of acute kidney injury (AKI), gastrointestinal events (GIE) and hypocalcaemia (HC) in patients with moderate-severe CKD.

Published
2018

25. Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access.

Author

Caskey F., Hawley C.M., Levin A., Wang A., Porter A., Sautenent B., Reddy B., Hemmelgarn B., Schiller B., Wheeler D., Harris D., Schatell D., Lacson E., Bavlovlenkov E., Strippoli G., Feldman H., Apata I., Tordoir J., Flythe J., Gill J., Kusek J., Abbott K., Dember L., Cervantes L., Moist L., Poole L., Tonelli M., Gallieni M., Elliot M., Klusmeyer M., Josephson M., Robbin M., Riella M., Evangelidis N., Tugwell P., Ravani P., Roy-Chaudhury P., Mehrotra R., Pecoits-Filho R., Crowe S., Evered S., Segerer S., Fadem S., McDonald S., Sprague S., Palmer S., Poma T., Sikirica V., Jha V., van Biesen W., Winkelmayer W., Mayers A., Bell B., Carter J., Hardy K., Ennis M., Johnson M., Rouse N., Wright S., Harris T., Muhammad U., McNorton V., Mayers D., Ennis D., Kerr P., Polkinghorne K.R., Viecelli A.K., Tong A., O'Lone E., Ju A., Hanson C.S., Sautenet B., Craig J.C., Manns B., Howell M., Chemla E., Hooi L.-S., Johnson D.W., Lee T., Lok C.E., Quinn R.R., Vachharajani T., Vanholder R., Zuo L., Caskey F., Hawley C.M., Levin A., Wang A., Porter A., Sautenent B., Reddy B., Hemmelgarn B., Schiller B., Wheeler D., Harris D., Schatell D., Lacson E., Bavlovlenkov E., Strippoli G., Feldman H., Apata I., Tordoir J., Flythe J., Gill J., Kusek J., Abbott K., Dember L., Cervantes L., Moist L., Poole L., Tonelli M., Gallieni M., Elliot M., Klusmeyer M., Josephson M., Robbin M., Riella M., Evangelidis N., Tugwell P., Ravani P., Roy-Chaudhury P., Mehrotra R., Pecoits-Filho R., Crowe S., Evered S., Segerer S., Fadem S., McDonald S., Sprague S., Palmer S., Poma T., Sikirica V., Jha V., van Biesen W., Winkelmayer W., Mayers A., Bell B., Carter J., Hardy K., Ennis M., Johnson M., Rouse N., Wright S., Harris T., Muhammad U., McNorton V., Mayers D., Ennis D., Kerr P., Polkinghorne K.R., Viecelli A.K., Tong A., O'Lone E., Ju A., Hanson C.S., Sautenet B., Craig J.C., Manns B., Howell M., Chemla E., Hooi L.-S., Johnson D.W., Lee T., Lok C.E., Quinn R.R., Vachharajani T., Vanholder R., and Zuo L.

Abstract

Vascular access outcomes in hemodialysis are critically important for patients and clinicians, but frequently are neither patient relevant nor measured consistently in randomized trials. A Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) consensus workshop was convened to discuss the development of a core outcome measure for vascular access. 13 patients/caregivers and 46 professionals (clinicians, policy makers, industry representatives, and researchers) attended. Participants advocated for vascular access function to be a core outcome based on the broad applicability of function regardless of access type, involvement of a multidisciplinary team in achieving a functioning access, and the impact of access function on quality of life, survival, and other access-related outcomes. A core outcome measure for vascular access required demonstrable feasibility for implementation across different clinical and trial settings. Participants advocated for a practical and flexible outcome measure with a simple actionable definition. Integrating patients' values and preferences was warranted to enhance the relevance of the measure. Proposed outcome measures for function included "uninterrupted use of the access without the need for interventions" and "ability to receive prescribed dialysis," but not "access blood flow," which was deemed too expensive and unreliable. These recommendations will inform the definition and implementation of a core outcome measure for vascular access function in hemodialysis trials.Copyright © 2018 National Kidney Foundation, Inc.

Published
2018

26. Use of oral bisphosphonates and bone mineral density changes in moderate-severe (Stage 3B+) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark

Author

Ali, M, Ernst, M, Caskey, F, Arden, N, Ben-Shlomo, Y, Nybo, M, Rubin, K, Judge, A, Cooper, C, Javaid, M, Hermann, P, Abrahamsen, B, and Prieto-Alhambra, D

Abstract

In addition to safety concerns, there is a paucity of data for oral bisphosphonates (oBP) to improve bone mineral density (BMD) in patients with moderate or severe chronic kidney disease (CKD). We linked all BMD measurements in the Funen area (pop 478,000, Denmark) to biochemistry, national health registries, and filled prescriptions to study the association between oBP use and BMD changes.

Published
2017

27. Health related quality of life and life-style factors are associated with decline in nutritional status in older adults with chronic kidney disease; the equal study

Author

Windahl, K., primary, Faxén Irving, G., additional, Korkeila Lidén, M., additional, Almquist, T., additional, Stenvinkel, P., additional, Chesnaye, N., additional, Gaetana Porto, T., additional, Torino, C., additional, Klinger, M., additional, Szymczak, M., additional, Janmaat, C., additional, Postorini, M., additional, Drechsler, C., additional, Hole, B., additional, Caskey, F., additional, Wanner, C., additional, Dekker, F., additional, Jager, K., additional, and Evans, M., additional

Published
2018
Full Text
View/download PDF

28. SP228A MULTICENTRE, STEPPED-WEDGE CLUSTER RANDOMISED TRIAL OF A COMPLEX INTERVENTION TO REDUCE HARM ASSOCIATED WITH ACUTE KIDNEY INJURY

Author

Selby, N, primary, Casula, A, additional, Lamming, L, additional, Stoves, J, additional, Samarasinghe, Y, additional, Lewington, A, additional, Roberts, R, additional, Shah, N, additional, Fluck, R, additional, Johnson, M, additional, Jackson, N, additional, AJones, C, additional, Mohammad, M, additional, and Caskey, F, additional

Published
2018
Full Text
View/download PDF

30. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease

Author

Spithoven, E., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Caskey, F., Collart, F., Finne, P., Fogarty, D., Groothoff, J., Hoitsma, A., Nogier, M., Postorino, M., Ravani, P., Zurriaga, O., Jager, K., Gansevoort, R., ERA EDTA Registry, Eurocyst, C., Wgikd, Aresté N, W.G.I.K.D., Arias, M., Couchoud, C., Budde, K., Chauveau, D., Devuyst, O., Ecder, T., Eckardt, K., Köttgen, A., Ong, A., Petzold, K., Pirson, Y., Remuzzi, G., Torra, R., Sandford, R., Serra, A., Tesar, V., Walz, G., Wüthrich, R., Antignac, C., Bindels, R., Emma, F., Maxwell, P., Ronco, P., Schaefer, F., ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, Medical Informatics, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Other Research, Paediatric Nephrology, University of Zurich, Gansevoort, Ron T, Cardiovascular Centre (CVC), and Groningen Kidney Center (GKC)

Subjects
Change over time, medicine.medical_specialty, EUROPE, medicine.medical_treatment, Population, Autosomal dominant polycystic kidney disease, PROGRESSION, urologic and male genital diseases, 10052 Institute of Physiology, Internal medicine, medicine, In patient, Renal replacement therapy, education, BLOOD-PRESSURE CONTROL, POPULATION, ADPKD, Epidemiology, Renoprotective therapy, Nephrology, Settore MED/14 - Nefrologia, Kidney, education.field_of_study, 2727 Nephrology, business.industry, urogenital system, Incidence (epidemiology), Other Research Radboud Institute for Health Sciences [Radboudumc 0], medicine.disease, TRENDS, female genital diseases and pregnancy complications, Surgery, medicine.anatomical_structure, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], 570 Life sciences, biology, GROWTH, epidemiology, business, Kidney disease, renoprotective therapy
Abstract

Item does not contain fulltext Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to postpone the need for renal replacement therapy (RRT) in non-ADPKD patients have also been tested in ADPKD patients, but with inconclusive results. To help resolve this we determined changes in RRT incidence rates as an indicator for increasing effective renoprotection over time in ADPKD. We analyzed data from the European Renal Association-European Dialyses and Transplant Association Registry on 315,444 patients starting RRT in 12 European countries between 1991 and 2010, grouped into four 5-year periods. Of them, 20,596 were due to ADPKD. Between the first and last period the mean age at onset of RRT increased from 56.6 to 58.0 years. The age- and gender-adjusted incidence rate of RRT for ADPKD increased slightly over the four periods from 7.6 to 8.3 per million population. No change over time was found in the incidence of RRT for ADPKD up to age 50, whereas in recent time periods the incidence in patients above the age of 70 clearly increased. Among countries there was a significant positive association between RRT take-on rates for non-ADPKD kidney disease and ADPKD. Thus, the increased age at onset of RRT is most likely due to an increased access for elderly ADPKD patients or lower competing risk prior to the start of RRT rather than the consequence of effective emerging renoprotective treatments for ADPKD. 01 december 2014

Published
2014

31. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival-an analysis of data from the ERA-EDTA Registry

Author

Spithoven, E.M., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Abad, J.M., Aresté, N., De La Torre, R.A., Caskey, F., Couchoud, C., Finne, P., Heaf, J., Hoitsma, A., De Meester, J., Pascual, J., Postorino, M., Ravani, P., Zurriaga, O., Jager, K.J., Gansevoort, R.T., De Los Ángeles García Bazaga, M., Metcalfe, W., Rodrigo, E., Quirós, J.R., Budde, K., Chauveau, D., Devuyst, O., Ecder, T., Eckardt, K.U., Köttgen, A., Ong, A.C., Petzold, K., Pirson, Y., Remuzzi, G., Torra, R., Sandford, R.N., Serra, A.L., Tesar, V., Walz, G., Wüthrich, R.P., Antignac, C., Bindels, R., Emma, F., Maxwell, P.H., Ronco, P., Schaefer, F., University of Zurich, Gansevoort, Ron T, ACS - Amsterdam Cardiovascular Sciences, APH - Amsterdam Public Health, Medical Informatics, Cardiovascular Centre (CVC), and Groningen Kidney Center (GKC)

Subjects
Male, Time Factors, PROGNOSIS, 2747 Transplantation, medicine.medical_treatment, MULTICENTER, Disease, urologic and male genital diseases, 10052 Institute of Physiology, Epidemiology, Polycystic Kidney, EPIDEMIOLOGY, Registries, PERITONEAL-DIALYSIS, COMPLICATIONS, 2727 Nephrology, Medicine (all), Middle Aged, female genital diseases and pregnancy complications, Europe, Survival Rate, Autosomal Dominant, Nephrology, 10076 Center for Integrative Human Physiology, Female, TRIAL, Hemodialysis, renal replacement therapy, medicine.medical_specialty, COST-ANALYSIS, prevalence, Urology, Autosomal dominant polycystic kidney disease, 610 Medicine & health, survival, Peritoneal dialysis, Renal Dialysis, medicine, Humans, Renal replacement therapy, Intensive care medicine, Survival rate, Aged, ADPKD, Settore MED/14 - Nefrologia, Transplantation, urogenital system, business.industry, MORTALITY, Other Research Radboud Institute for Health Sciences [Radboudumc 0], medicine.disease, epidemiology, Polycystic Kidney, Autosomal Dominant, Prevalence, Renal Replacement Therapy, 570 Life sciences, biology, business
Abstract

Item does not contain fulltext BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common renal disease requiring renal replacement therapy (RRT). Still, there are few epidemiological data on the prevalence of, and survival on RRT for ADPKD. METHODS: This study used data from the ERA-EDTA Registry on RRT prevalence and survival on RRT in 12 European countries with 208 million inhabitants. We studied four 5-year periods (1991-2010). Survival analysis was performed by the Kaplan-Meier method and by Cox proportional hazards regression. RESULTS: From the first to the last study period, the prevalence of RRT for ADPKD increased from 56.8 to 91.1 per million population (pmp). The percentage of prevalent RRT patients with ADPKD remained fairly stable at 9.8%. Two-year survival of ADPKD patients on RRT (adjusted for age, sex and country) increased significantly from 89.0 to 92.8%, and was higher than for non-ADPKD subjects. Improved survival was noted for all RRT modalities: haemodialysis [adjusted hazard ratio for mortality during the last versus first time period 0.75 (95% confidence interval 0.61-0.91), peritoneal dialysis 0.55 (0.38-0.80) and transplantation 0.52 (0.32-0.74)]. Cardiovascular mortality as a proportion of total mortality on RRT decreased more in ADPKD patients (from 53 to 29%), than in non-ADPKD patients (from 44 to 35%). Of note, the incidence rate of RRT for ADPKD remained relatively stable at 7.6 versus 8.3 pmp from the first to the last study period, which will be discussed in detail in a separate study. CONCLUSIONS: In ADPKD patients on RRT, survival has improved markedly, especially due to a decrease in cardiovascular mortality. This has led to a considerable increase in the number of ADPKD patients being treated with RRT. 01 september 2014

Published
2014

32. Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales and Northern Ireland from 2003 to 2008: national and centre-specific analyses

Author

Caskey, F., Webb, L., Gilg, J., and Fogarty, Damian

Subjects
urologic and male genital diseases
Abstract

Introduction: The prevalence of comorbidities in incident renal replacement therapy (RRT) patients changes with age and varies between ethnic groups. This study describes these associations and the independent effect of comorbidities on outcomes. Methods: Adult patients starting RRT between 2003 and 2008 in centres reporting to the UK Renal Registry (UKRR) with data on comorbidity (n ¼ 14,909) were included. The UKRR studied the association of comorbidity with patient demographics, treatment modality, haemoglobin, renal function at start of RRT and subsequent listing for kidney transplantation. The relationship between comorbidities and mortality at 90 days and one year after 90 days from start of RRT was explored using Cox regression. Results: Completeness of comorbidity data was 40.0% compared with 54.3% in 2003. Of patients with data, 53.8% had one or more comorbidities. Diabetes mellitus and ischaemic heart disease were the most common conditions seen in 30.1% and 22.7% of patients respectively. Current smoking was recorded for 14.5% of incident RRT patients in the 6-year period. Comorbidities became more common with increasing age in all ethnic groups although the difference between the 65–74 and 75+ age groups was not significant. Within each age group, South Asians and Blacks had lower rates of comorbidity, despite higher rates of diabetes mellitus. In multivariate survival analysis, malignancy and ischaemic/neuropathic ulcers were the strongest independent predictors of poor survival at 1 year after 90 days from the start of RRT. Conclusion: Differences in prevalence of comorbid illnesses in incident RRT patients may reflect variation in access to health care or competing risk prior to commencing treatment. At the same time, smoking rates remained high in this ‘at risk’ population. Further work on this and ways to improve comorbidity reporting should be priorities for 2010–11.

Published
2010

33. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.

Author

Spithoven, E.M., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Caskey, F., Collart, F., Finne, P., Fogarty, D.G., Groothoff, J.W., Hoitsma, A.J., Nogier, M.B., Postorino, M., Ravani, P., Zurriaga, O., Jager, K.J., Gansevoort, R.T., Bindels, R.J.M., et al., Spithoven, E.M., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Caskey, F., Collart, F., Finne, P., Fogarty, D.G., Groothoff, J.W., Hoitsma, A.J., Nogier, M.B., Postorino, M., Ravani, P., Zurriaga, O., Jager, K.J., Gansevoort, R.T., Bindels, R.J.M., and et al.

Abstract

1 december 2014, Item does not contain fulltext, Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to postpone the need for renal replacement therapy (RRT) in non-ADPKD patients have also been tested in ADPKD patients, but with inconclusive results. To help resolve this we determined changes in RRT incidence rates as an indicator for increasing effective renoprotection over time in ADPKD. We analyzed data from the European Renal Association-European Dialyses and Transplant Association Registry on 315,444 patients starting RRT in 12 European countries between 1991 and 2010, grouped into four 5-year periods. Of them, 20,596 were due to ADPKD. Between the first and last period the mean age at onset of RRT increased from 56.6 to 58.0 years. The age- and gender-adjusted incidence rate of RRT for ADPKD increased slightly over the four periods from 7.6 to 8.3 per million population. No change over time was found in the incidence of RRT for ADPKD up to age 50, whereas in recent time periods the incidence in patients above the age of 70 clearly increased. Among countries there was a significant positive association between RRT take-on rates for non-ADPKD kidney disease and ADPKD. Thus, the increased age at onset of RRT is most likely due to an increased access for elderly ADPKD patients or lower competing risk prior to the start of RRT rather than the consequence of effective emerging renoprotective treatments for ADPKD.

Published
2014

34. DIALYSIS ANAEMIA

Author

Locatelli, F., primary, Choukroun, G., additional, Fliser, D., additional, Moecks, J., additional, Wiggenhauser, A., additional, Gupta, A., additional, Swinkels, D. W., additional, Lin, V., additional, Guss, C., additional, Pratt, R., additional, Carrilho, P., additional, Martins, A. R., additional, Alves, M., additional, Mateus, A., additional, Gusmao, L., additional, Parreira, L., additional, Assuncao, J., additional, Rodrigues, I., additional, Stamopoulos, D., additional, Mpakirtzi, N., additional, Afentakis, N., additional, Grapsa, E., additional, Zitt, E., additional, Sturm, G., additional, Kronenberg, F., additional, Neyer, U., additional, Knoll, F., additional, Lhotta, K., additional, Weiss, G., additional, Robinson, B. M., additional, Larkina, M., additional, Bieber, B., additional, Kleophas, W., additional, Li, Y., additional, Locatelli, F., additional, McCullough, K., additional, Nolen, J. G., additional, Port, F. K., additional, Pisoni, R. L., additional, Kalicki, R. M., additional, Uehlinger, D. E., additional, Ogawa, C., additional, Kanda, F., additional, Tomosugi, N., additional, Maeda, T., additional, Kuji, T., additional, Fujikawa, T., additional, Shino, M., additional, Shibata, K., additional, Kaneda, T., additional, Nishihara, M., additional, Satta, H., additional, Kawata, S.-I., additional, Koguchi, N., additional, Tamura, K., additional, Hirawa, N., additional, Toya, Y., additional, Umemura, S., additional, Chanliau, J., additional, Martin, H., additional, Stamatelou, K., additional, Gonzalez-Tabares, L., additional, Manamley, N., additional, Farouk, M., additional, Addison, J., additional, Donck, J., additional, Schneider, A., additional, Gutjahr-Lengsfeld, L., additional, Ritz, E., additional, Scharnagl, H., additional, Gelbrich, G., additional, Pilz, S., additional, Macdougall, I. C., additional, Wanner, C., additional, Drechsler, C., additional, Kuntsevich, V., additional, Charen, E., additional, Kobena, D., additional, Sheth, N., additional, Siktel, H., additional, Levin, N. W., additional, Winchester, J. F., additional, Kotanko, P., additional, Kaysen, G., additional, Kuragano, T., additional, Kida, A., additional, Yahiro, M., additional, Nanami, M., additional, Nagasawa, Y., additional, Hasuike, Y., additional, Nakanishi, T., additional, Dimitratou, V., additional, Griveas, I., additional, Lianos, E., additional, Sasaki, Y., additional, Yamazaki, S., additional, Fujita, K., additional, Kurasawa, M., additional, Yorozu, K., additional, Shimonaka, Y., additional, Suzuki, N., additional, Yamamoto, M., additional, Zwiech, R., additional, Szczepa ska, J., additional, Bruzda-Zwiech, A., additional, Rao, A., additional, Gilg, J., additional, Caskey, F., additional, Kirkpantur, A., additional, Balci, M. M., additional, Turkvatan, A., additional, Afsar, B., additional, Alkis, M., additional, Mandiroglu, F., additional, Kim, Y. O., additional, Yoon, S. A., additional, Kim, Y. S., additional, Choi, S. J., additional, Min, J. W., additional, Cheong, M. A., additional, Oue, M., additional, Yamamoto, K., additional, Kimura, T., additional, Fukao, W., additional, Kaibe, S., additional, Djuric, P. S., additional, Ikonomovski, J., additional, Tosic, J., additional, Jankovic, A., additional, Majster, Z., additional, Stankovic Popovic, V., additional, Dimkovic, N., additional, Aicardi Spalloni, V., additional, Del Vecchio, L., additional, Longhi, S., additional, Violo, L., additional, La Milia, V., additional, Pontoriero, G., additional, Macdougall, I., additional, Rumjon, A., additional, Mangahis, E., additional, Goldstein, L., additional, Ryzlewicz, T., additional, Becker, F., additional, Kilgallon, W., additional, Fukasawa, M., additional, Otake, Y., additional, Yamagishi, T., additional, Kamiyama, M., additional, Kobayashi, H., additional, Takeda, M., additional, Toida, T., additional, Sato, Y., additional, and Fujimoto, S., additional

Published
2014
Full Text
View/download PDF

35. Renal replacement therapy in Europe: a summary of the 2011 ERA-EDTA Registry Annual Report

Author

Noordzij, M., primary, Kramer, A., additional, Abad Diez, J. M., additional, Alonso de la Torre, R., additional, Arcos Fuster, E., additional, Bikbov, B. T., additional, Bonthuis, M., additional, Bouzas Caamano, E., additional,  ala, S., additional, Caskey, F. J., additional, Castro de la Nuez, P., additional, Cernevskis, H., additional, Collart, F., additional, Diaz Tejeiro, R., additional, Djukanovic, L., additional, Ferrer-Alamar, M., additional, Finne, P., additional, Garcia Bazaga, M. d. l. A., additional, Garneata, L., additional, Golan, E., additional, Gonzalez Fernandez, R., additional, Heaf, J. G., additional, Hoitsma, A., additional, Ioannidis, G. A., additional, Kolesnyk, M., additional, Kramar, R., additional, Lasalle, M., additional, Leivestad, T., additional, Lopot, F., additional, van de Luijtgaarden, M. W. M., additional, Macario, F., additional, Magaz, A., additional, Martin Escobar, E., additional, de Meester, J., additional, Metcalfe, W., additional, Ots-Rosenberg, M., additional, Palsson, R., additional, Pinera, C., additional, Pippias, M., additional, Prutz, K. G., additional, Ratkovic, M., additional, Resi , H., additional, Rodriguez Hernandez, A., additional, Rutkowski, B., additional, Spustova, V., additional, Stel, V. S., additional, Stojceva-Taneva, O., additional, Suleymanlar, G., additional, Wanner, C., additional, and Jager, K. J., additional

Published
2014
Full Text
View/download PDF

41. Epidemiology and outcome research in CKD 5D

Author

Coentrao, L., primary, Ribeiro, C., additional, Santos-Araujo, C., additional, Neto, R., additional, Pestana, M., additional, Kleophas, W., additional, Karaboyas, A., additional, LI, Y., additional, Bommer, J., additional, Pisoni, R., additional, Robinson, B., additional, Port, F., additional, Celik, G., additional, Burcak Annagur, B., additional, Yilmaz, M., additional, Demir, T., additional, Kara, F., additional, Trigka, K., additional, Dousdampanis, P., additional, Vaitsis, N., additional, Aggelakou-Vaitsi, S., additional, Turkmen, K., additional, Guney, I., additional, Turgut, F., additional, Altintepe, L., additional, Tonbul, H. Z., additional, Abdel-Rahman, E., additional, Sclauzero, P., additional, Galli, G., additional, Barbati, G., additional, Carraro, M., additional, Panzetta, G. O., additional, Van Diepen, M., additional, Schroijen, M., additional, Dekkers, O., additional, Dekker, F., additional, Sikole, A., additional, Severova- Andreevska, G., additional, Trajceska, L., additional, Gelev, S., additional, Amitov, V., additional, Pavleska- Kuzmanovska, S., additional, Rayner, H., additional, Vanholder, R., additional, Hecking, M., additional, Jung, B., additional, Leung, M., additional, Huynh, F., additional, Chung, T., additional, Marchuk, S., additional, Kiaii, M., additional, Er, L., additional, Werb, R., additional, Chan-Yan, C., additional, Beaulieu, M., additional, Malindretos, P., additional, Makri, P., additional, Zagkotsis, G., additional, Koutroumbas, G., additional, Loukas, G., additional, Nikolaou, E., additional, Pavlou, M., additional, Gourgoulianni, E., additional, Paparizou, M., additional, Markou, M., additional, Syrgani, E., additional, Syrganis, C., additional, Raimann, J., additional, Usvyat, L. A., additional, Bhalani, V., additional, Levin, N. W., additional, Kotanko, P., additional, Huang, X., additional, Stenvinkel, P., additional, Qureshi, A. R., additional, Riserus, U., additional, Cederholm, T., additional, Barany, P., additional, Heimburger, O., additional, Lindholm, B., additional, Carrero, J. J., additional, Chang, J. H., additional, Sung, J. Y., additional, Jung, J. Y., additional, Lee, H. H., additional, Chung, W., additional, Kim, S., additional, Han, J. S., additional, Na, K. Y., additional, Fragoso, A., additional, Pinho, A., additional, Malho, A., additional, Silva, A. P., additional, Morgado, E., additional, Leao Neves, P., additional, Joki, N., additional, Tanaka, Y., additional, Iwasaki, M., additional, Kubo, S., additional, Hayashi, T., additional, Takahashi, Y., additional, Hirahata, K., additional, Imamura, Y., additional, Hase, H., additional, Castledine, C., additional, Gilg, J., additional, Rogers, C., additional, Ben-Shlomo, Y., additional, Caskey, F., additional, Sandhu, J. S., additional, Bajwa, G. S., additional, Kansal, S., additional, Sandhu, J., additional, Jayanti, A., additional, Nikam, M., additional, Ebah, L., additional, Summers, A., additional, Mitra, S., additional, Agar, J., additional, Perkins, A., additional, Simmonds, R., additional, Tjipto, A., additional, Amet, S., additional, Launay-Vacher, V., additional, Laville, M., additional, Tricotel, A., additional, Frances, C., additional, Stengel, B., additional, Gauvrit, J.-Y., additional, Grenier, N., additional, Reinhardt, G., additional, Clement, O., additional, Janus, N., additional, Rouillon, L., additional, Choukroun, G., additional, Deray, G., additional, Bernasconi, A., additional, Waisman, R., additional, Montoya, A. P., additional, Liste, A. A., additional, Hermes, R., additional, Muguerza, G., additional, Heguilen, R., additional, Iliescu, E. L., additional, Martina, V., additional, Rizzo, M. A., additional, Magenta, P., additional, Lubatti, L., additional, Rombola, G., additional, Gallieni, M., additional, Loirat, C., additional, Mellerio, H., additional, Labeguerie, M., additional, Andriss, B., additional, Savoye, E., additional, Lassale, M., additional, Jacquelinet, C., additional, Alberti, C., additional, Aggarwal, Y., additional, Baharani, J., additional, Tabrizian, S., additional, Ossareh, S., additional, Zebarjadi, M., additional, Azevedo, P., additional, Travassos, F., additional, Frade, I., additional, Almeida, M., additional, Queiros, J., additional, Silva, F., additional, Cabrita, A., additional, Rodrigues, R., additional, Couchoud, C., additional, Kitty, J., additional, Benedicte, S., additional, Fergus, C., additional, Cecile, C., additional, Sahar, B., additional, Emmanuel, V., additional, Christian, J., additional, Rene, E., additional, Barahimi, H., additional, Mahdavi-Mazdeh, M., additional, Nafar, M., additional, Petruzzi, M., additional, De Benedittis, M., additional, Sciancalepore, M., additional, Gargano, L., additional, Natale, P., additional, Vecchio, M. C., additional, Saglimbene, V., additional, Pellegrini, F., additional, Gentile, G., additional, Stroumza, P., additional, Frantzen, L., additional, Leal, M., additional, Torok, M., additional, Bednarek, A., additional, Dulawa, J., additional, Celia, E., additional, Gelfman, R., additional, Hegbrant, J., additional, Wollheim, C., additional, Palmer, S., additional, Johnson, D. W., additional, Ford, P. J., additional, Craig, J. C., additional, Strippoli, G. F., additional, Ruospo, M., additional, El Hayek, B., additional, Hayek, B., additional, Baamonde, E., additional, Bosch, E., additional, Ramirez, J. I., additional, Perez, G., additional, Ramirez, A., additional, Toledo, A., additional, Lago, M. M., additional, Garcia-Canton, C., additional, Checa, M. D., additional, Canaud, B., additional, Lantz, B., additional, Granger-Vallee, A., additional, Lertdumrongluk, P., additional, Molinari, N., additional, Ethier, J., additional, Jadoul, M., additional, Gillespie, B., additional, Bond, C., additional, Wang, S., additional, Alfieri, T., additional, Braunhofer, P., additional, Newsome, B., additional, Wang, M., additional, Bieber, B., additional, Guidinger, M., additional, Zuo, L., additional, Yu, X., additional, Yang, X., additional, Qian, J., additional, Chen, N., additional, Albert, J., additional, Yan, Y., additional, Ramirez, S., additional, Beresan, M., additional, Lapidus, A., additional, Canteli, M., additional, Tong, A., additional, Manns, B., additional, Craig, J., additional, Strippoli, G., additional, Mortazavi, M., additional, Vahdatpour, B., additional, Shahidi, S., additional, Ghasempour, A., additional, Taheri, D., additional, Dolatkhah, S., additional, Emami Naieni, A., additional, Ghassami, M., additional, Khan, M., additional, Abdulnabi, K., additional, Pai, P., additional, Vecchio, M., additional, Muqueet, M. A., additional, Hasan, M. J., additional, Kashem, M. A., additional, Dutta, P. K., additional, Liu, F. X., additional, Noe, L., additional, Quock, T., additional, Neil, N., additional, Inglese, G., additional, Motamed Najjar, M., additional, Bahmani, B., additional, Shafiabadi, A., additional, Helve, J., additional, Haapio, M., additional, Groop, P.-H., additional, Gronhagen-Riska, C., additional, Finne, P., additional, Sund, R., additional, Cai, M., additional, Baweja, S., additional, Clements, A., additional, Kent, A., additional, Reilly, R., additional, Taylor, N., additional, Holt, S., additional, Mcmahon, L., additional, Carter, M., additional, Van der Sande, F. M., additional, Kooman, J., additional, Malhotra, R., additional, Ouellet, G., additional, Penne, E. L., additional, Thijssen, S., additional, Etter, M., additional, Tashman, A., additional, Guinsburg, A., additional, Grassmann, A., additional, Barth, C., additional, Marelli, C., additional, Marcelli, D., additional, Von Gersdorff, G., additional, Bayh, I., additional, Scatizzi, L., additional, Lam, M., additional, Schaller, M., additional, Toffelmire, T., additional, Wang, Y., additional, Sheppard, P., additional, Neri, L., additional, Andreucci, V. A., additional, Rocca-Rey, L. A., additional, Bertoli, S. V., additional, Brancaccio, D., additional, De Berardis, G., additional, Lucisano, G., additional, Johnson, D., additional, Nicolucci, A., additional, Bonifati, C., additional, Navaneethan, S. D., additional, Montinaro, V., additional, Zsom, M., additional, Bednarek-Skublewska, A., additional, Graziano, G., additional, Ferrari, J. N., additional, Santoro, A., additional, Zucchelli, A., additional, Triolo, G., additional, Maffei, S., additional, De Cosmo, S., additional, Manfreda, V. M., additional, Juillard, L., additional, Rousset, A., additional, Butel, F., additional, Girardot-Seguin, S., additional, Hannedouche, T., additional, Isnard, M., additional, Berland, Y., additional, Vanhille, P., additional, Ortiz, J.-P., additional, Janin, G., additional, Nicoud, P., additional, Touam, M., additional, Bruce, E., additional, Grace, B., additional, Clayton, P., additional, Cass, A., additional, Mcdonald, S., additional, Furumatsu, Y., additional, Kitamura, T., additional, Fujii, N., additional, Ogata, S., additional, Nakamoto, H., additional, Iseki, K., additional, Tsubakihara, Y., additional, Chien, C.-C., additional, Wang, J.-J., additional, Hwang, J.-C., additional, Wang, H.-Y., additional, Kan, W.-C., additional, Kuster, N., additional, Patrier, L., additional, Bargnoux, A.-S., additional, Morena, M., additional, Dupuy, A.-M., additional, Badiou, S., additional, Cristol, J.-P., additional, Desmet, J.-M., additional, Fernandes, V., additional, Collart, F., additional, Spinogatti, N., additional, Pochet, J.-M., additional, Dratwa, M., additional, Goffin, E., additional, Nortier, J., additional, Zilisteanu, D. S., additional, Voiculescu, M., additional, Rusu, E., additional, Achim, C., additional, Bobeica, R., additional, Balanica, S., additional, Atasie, T., additional, Florence, S., additional, Anne-Marie, S., additional, Michel, L., additional, Cyrille, C., additional, Strakosha, A., additional, Pasko, N., additional, Kodra, S., additional, Thereska, N., additional, Lowney, A., additional, Lowney, E., additional, Grant, R., additional, Murphy, M., additional, Casserly, L., additional, O' Brien, T., additional, Plant, W. D., additional, Radic, J., additional, Ljutic, D., additional, Kovacic, V., additional, Radic, M., additional, Dodig-Curkovic, K., additional, Sain, M., additional, Jelicic, I., additional, Hamano, T., additional, Nakano, C., additional, Yonemoto, S., additional, Okuno, A., additional, Katayama, M., additional, Isaka, Y., additional, Nordio, M., additional, Limido, A., additional, Postorino, M., additional, Nichelatti, M., additional, Khil, M., additional, Dudar, I., additional, Khil, V., additional, Shifris, I., additional, Momtaz, M., additional, Soliman, A. R., additional, El Lawindi, M. I., additional, Dzekova-Vidimliski, P., additional, Pavleska-Kuzmanovska, S., additional, Nikolov, I., additional, Selim, G., additional, Shoji, T., additional, Kakiya, R., additional, Tatsumi-Shimomura, N., additional, Tsujimoto, Y., additional, Tabata, T., additional, Shima, H., additional, Mori, K., additional, Fukumoto, S., additional, Tahara, H., additional, Koyama, H., additional, Emoto, M., additional, Ishimura, E., additional, Nishizawa, Y., additional, and Inaba, M., additional

Published
2012
Full Text
View/download PDF

42. CKD 5D epidemiology and outcomes

Author

Arnold, R., primary, Pussell, B. A., additional, Grinius, V., additional, Kiernan, M. C., additional, Lin, C. S.-Y., additional, Krishnan, A. V., additional, Defedele, D., additional, Loiacono, E., additional, Puccinelli, M. P., additional, Peruzzi, L., additional, Maffei, S., additional, Camilla, R., additional, Gallo, R., additional, Triolo, G., additional, Bergamo, D., additional, Palazzo, E., additional, Vergano, L., additional, Campolo, F., additional, Amore, A., additional, Coppo, R., additional, Schneider, A., additional, Schneider, M. P., additional, Jardine, A. G., additional, Wanner, C., additional, Drechsler, C., additional, Hecking, M., additional, Karaboyas, A., additional, Rayner, H., additional, Saran, R., additional, Sen, A., additional, Inaba, M., additional, Bommer, J., additional, Horl, W., additional, Pisoni, R., additional, Robinson, B., additional, Sunder-Plassmann, G., additional, Port, F., additional, Usvyat, L. A., additional, Thijssen, S., additional, Kotanko, P., additional, Levin, N. W., additional, Castledine, C., additional, Gilg, J., additional, Rogers, C., additional, Ben-Shlomo, Y., additional, and Caskey, F., additional

Published
2012
Full Text
View/download PDF

43. Clinical studies in CKD 1-5

Author

Szotowska, M., primary, Chudek, J., additional, Wiecek, A., additional, Adamczak, M., additional, Bossola, M., additional, DI Stasio, E., additional, Antocicco, M., additional, Silvestri, P., additional, Tazza, L., additional, Stec, A., additional, Koziol - Montewka, M., additional, Ksiazek, A., additional, Birnie, K., additional, Caskey, F., additional, Geeson, A. I., additional, Dairaghi, D., additional, Johnson, D., additional, Leleti, M., additional, Miao, S., additional, Xiao, H., additional, Jennette, J. C., additional, Powers, J. P., additional, Seitz, L., additional, Wang, Y., additional, Jaen, J. C., additional, Schall, T. J., additional, Bekker, P., additional, Arai, H., additional, Hayashi, H., additional, Sugiyama, K., additional, Yamamoto, K., additional, Koide, S., additional, Murakami, K., additional, Tomita, M., additional, Hasegawa, M., additional, Yuzawa, Y., additional, Karasavvidou, D., additional, Kalaitzidis, R., additional, Spanos, G., additional, Pappas, K., additional, Tatsioni, A., additional, Siamopoulos, K., additional, Zhang, Y.-Y., additional, Tang, Z., additional, Chen, D.-M., additional, Zhang, M.-C., additional, Liu, Z.-H., additional, Milovanov, Y., additional, Milovanova, L., additional, Kozlovskaya, L., additional, Klein, C., additional, Noertersheuser, P., additional, Mensing, S., additional, Teuscher, N., additional, Meyer, C., additional, Dumas, E., additional, Awni, W., additional, Dezfoolian, H., additional, Samuelsson, O., additional, Svensson, M., additional, Yasuda, Y., additional, Kato, S., additional, Tsuboi, N., additional, Sato, W., additional, Maruyama, S., additional, Imai, E., additional, Matsuo, S., additional, Sarafidis, P., additional, Blacklock, R., additional, Wood, E., additional, Rumjon, A., additional, Simmonds, S., additional, Fletcher-Rogers, J., additional, Elias, R., additional, Tucker, B., additional, Baynes, D., additional, Sharpe, C., additional, Vinen, K., additional, Hebbar, S., additional, Goldsberry, A., additional, Chin, M., additional, and Audhya, P., additional

Published
2012
Full Text
View/download PDF

46. Early referral and planned initiation of dialysis: what impact on quality of life?

Author

Caskey, F. J., Wordsworth, Sarah, Ben, T., de, Charro, Delcroix, C., van, Hamersvelt, Henderson, I., Kokolina, E., Khan, I. H., Ludbrook, Anne, Luman, M., Prescott, Gordon, Dobronravov, V., Caskey, F. J., Wordsworth, Sarah, Ben, T., de, Charro, Delcroix, C., van, Hamersvelt, Henderson, I., Kokolina, E., Khan, I. H., Ludbrook, Anne, Luman, M., Prescott, Gordon, and Dobronravov, V.

Abstract

Background. Early patient referral correlates with improved patient survival on dialysis. We examine whether early referral and a planned first dialysis affect quality of life (QoL).Methods. All patients commencing dialysis in nine centres in seven European countries between 1 July 1998 and 31 October 1999 were recruited. Definitions: early referral = followed by a nephrologist > 1 month before first dialysis (< 1 month = late referral); planned = early referral and previous serum creatinine > 300 mumol/l and non-urgent first dialysis (early referral and no creatinine > 300 gmol/l or urgent first dialysis = unplanned). QoL was measured at 8 weeks using a visual analogue scale (VAS) and Short Form 36 (SF-36).Results. VAS was significantly higher in early referral patients [mean (SD) 58.4 (20) vs 50.4 (19), P=0.005], particularly if the first dialysis was planned [60.7 (20) vs 54.2 (20), P = 0.03]. Planned patients also had higher SF-36 mental summary scores [45.4 (12) vs 39.7 (11), P = 0.003], role emotional scores [58.0 (43) vs 30.9 (38), P = 0.003], and mental health scores [63.7 (24) vs 54.6 (22), P = 0.01] than unplanned patients. Adjusting for centre and other confounding variables showed that having a planned first dialysis had an independent effect on QoL (VAS, and the SF-36's mental summary score, physical functioning, role physical, general health, role emotional and mental health). Early referral had no independent effect on QoL. Socio-economic status had an important positive effect on physical QoL.Conclusions. While the effect of early referral to a nephrologist on QoL appeared centre dependent, a smooth transition onto dialysis was associated with significantly better early QoL, independent of other variables.Background. Early patient referral correlates with improved patient survival on dialysis. We examine whether early referral and a planned first dialysis affect quality of life (QoL).Methods. All patients commencing dialysis in nine centres in seven

Published
2003

48. The EVEREST study: an international collaboration

Author

Caskey, F. J., primary, Stel, V. S., additional, Elliott, R. F., additional, Jager, K. J., additional, Covic, A., additional, Cusumano, A., additional, Geue, C., additional, Kramer, A., additional, Stengel, B., additional, and MacLeod, A. M., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results